相似文献
1
Monitoring target reduction in hepatic venous pressure gradient during pharmacological therapy of portal hypertension: a close look at the evidence.
Gut. 2004 Jan;53(1):143-8. doi: 10.1136/gut.53.1.143.
2
Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis.
Am J Gastroenterol. 2007 May;102(5):1116-26. doi: 10.1111/j.1572-0241.2007.01191.x. Epub 2007 Mar 27.
3
[Portal pressure should be measured on suspicion of portal hypertension].
Ugeskr Laeger. 2010 Dec 6;172(49):3411-3.
4
Pharmacologic prevention of variceal bleeding and rebleeding.
Hepatol Int. 2018 Feb;12(Suppl 1):68-80. doi: 10.1007/s12072-017-9833-y. Epub 2017 Dec 5.
5
Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study.
Aliment Pharmacol Ther. 2018 Apr;47(8):1162-1169. doi: 10.1111/apt.14576. Epub 2018 Feb 28.
6
Effect of propranolol and depot lanreotide SR on postprandial and circadian portal haemodynamics in cirrhosis.
Aliment Pharmacol Ther. 2003 Oct 15;18(8):777-84. doi: 10.1046/j.1365-2036.2003.01682.x.
7
Hepatic venous pressure gradient measurement in pre-primary and primary prophylaxis of variceal hemorrhage.
Ann Hepatol. 2013 Jan-Feb;12(1):22-9.
8
Variceal bleeding : pharmacological treatment and prophylactic strategies.
Drugs. 2008;68(16):2303-24. doi: 10.2165/0003495-200868160-00004.
9
Systematic review of HVPG measurement: statistics versus clinical applicability.
Gastroenterology. 2007 Mar;132(3):1201-2; author reply 1202-4. doi: 10.1053/j.gastro.2007.02.012.
10
Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis.
Am J Gastroenterol. 2006 Mar;101(3):506-12. doi: 10.1111/j.1572-0241.2006.00453.x.
引用本文的文献
1
Dose optimization of non-selective beta blockers among esophageal varices patients at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia: a hospital-based cross-sectional study.
BMC Gastroenterol. 2025 Feb 21;25(1):100. doi: 10.1186/s12876-025-03708-2.
2
The role of computed tomography for the prediction of esophageal variceal bleeding: Current status and future perspectives.
World J Gastrointest Endosc. 2023 Dec 16;15(12):681-689. doi: 10.4253/wjge.v15.i12.681.
3
Estimation of Physiologic Pressures: Invasive and Non-Invasive Techniques, AI Models, and Future Perspectives.
Sensors (Basel). 2023 Jun 20;23(12):5744. doi: 10.3390/s23125744.
4
Hepatic Venous Pressure Gradient.
Clin Liver Dis (Hoboken). 2021 Apr 13;17(3):144-148. doi: 10.1002/cld.1031. eCollection 2021 Mar.
5
Fibrosis index predicts variceal bleeding and reduces need for nonselective beta-blocker in compensated cirrhosis with initial small esophageal varices without red-color sign.
Ann Transl Med. 2020 Oct;8(19):1223. doi: 10.21037/atm-20-2444.
6
Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update.
Hepatol Int. 2017 Jan;11(1):1-30. doi: 10.1007/s12072-016-9760-3. Epub 2016 Oct 6.
7
Radiological score for hemorrhage in the patients with portal hypertension.
Int J Clin Exp Pathol. 2015 Sep 1;8(9):11517-23. eCollection 2015.
8
Assessment of risk of complications in cirrhosis using portal thallium scans.
World J Gastroenterol. 2014 Jan 7;20(1):228-34. doi: 10.3748/wjg.v20.i1.228.
9
Management of portal hypertension.
Postgrad Med J. 2004 Nov;80(949):634-41. doi: 10.1136/pgmj.2004.020446.
本文引用的文献
1
Spontaneous decrease in portal pressure with clinical improvement in cirrhosis.
N Engl J Med. 1960 Oct 13;263:734-9. doi: 10.1056/NEJM196010132631505.
2
Prevention of variceal rebleeding.
Lancet. 2003 Jun 28;361(9376):2244-5; author reply 2245. doi: 10.1016/S0140-6736(03)13749-X.
3
Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis.
Hepatology. 2003 Apr;37(4):902-8. doi: 10.1053/jhep.2003.50133.
4
Prevention of variceal rebleeding.
Lancet. 2003 Mar 15;361(9361):952-4. doi: 10.1016/S0140-6736(03)12778-X.
5
Current management of portal hypertension.
J Hepatol. 2003;38 Suppl 1:S54-68. doi: 10.1016/s0168-8278(02)00430-0.
6
Hepatic venous pressure gradient measurements to assess response to primary prophylaxis in patients with cirrhosis: a decision analytical study.
Aliment Pharmacol Ther. 2003 Jan;17(1):145-53. doi: 10.1046/j.1365-2036.2003.01391.x.
7
"A La Carte" treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleeding.
Hepatology. 2002 Dec;36(6):1361-6. doi: 10.1053/jhep.2002.36945.
8
A la carte or menu fixe: Improving pharmacologic therapy of portal hypertension.
Hepatology. 2002 Dec;36(6):1330-2. doi: 10.1053/jhep.2002.37354.
9
Endoscopic variceal banding vs. pharmacological therapy for the prevention of recurrent variceal hemorrhage: what makes the difference?
Gastroenterology. 2002 Oct;123(4):1388-91. doi: 10.1053/gast.2002.36364.
10
A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis.
Gastroenterology. 2002 Oct;123(4):1013-9. doi: 10.1053/gast.2002.35955.
Zotero 插件